Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,392.00-3.13%ETH$2,560.34-5.60%GOLD$4,116.70-1.68%OIL$89.92+0.54%
Smart Investors Daily
SID Premium
ON

NASDAQ · ONCY

Oncolytics Biotech Inc.

Healthcare · Biotechnology

$0.60

Up+$0.00 (+0.18%)

Updated Oct 7, 2026, 1:06 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
100.06M
P/E ratio
-3.94
Dividend yield
0.00%
52-week range
$0.58 – $1.47
Volume
859.73K
Avg. volume
891.91K

Price performance · ONCY

ONCY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

ONCY closed at $0.60 after 21 trading sessions, down 25.71% for the selected period.

Last close
$0.60
Period change
-25.71%
Period low
$0.60
Period high
$0.81
Daily close
View OHLC price history
ONCY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$0.60$0.605$0.5757$0.598859.73K
Oct 5, 2026$0.6362$0.6362$0.58$0.59691.94M
Oct 2, 2026$0.6521$0.6521$0.6211$0.631611.81K
Oct 1, 2026$0.668$0.6763$0.63$0.6412693.11K
Sep 30, 2026$0.68$0.6832$0.65$0.6682867.17K
Sep 29, 2026$0.67$0.68$0.66$0.6745784.33K
Sep 28, 2026$0.6846$0.718$0.663$0.6631.13M
Sep 25, 2026$0.69$0.694$0.667$0.6833826.24K
Sep 24, 2026$0.6765$0.686$0.6419$0.67921.21M
Sep 23, 2026$0.73$0.73$0.6602$0.67651.89M
Sep 22, 2026$0.76$0.7785$0.71$0.71332.08M
Sep 21, 2026$0.77$0.7898$0.7604$0.7663697.38K
Sep 18, 2026$0.7752$0.7775$0.7553$0.77491.9K
Sep 17, 2026$0.7817$0.802$0.77$0.77595.34K
Sep 16, 2026$0.7832$0.804$0.7606$0.7688958.77K
Sep 15, 2026$0.8328$0.84$0.78$0.78909.77K
Sep 14, 2026$0.7621$0.8501$0.7556$0.81271.4M
Sep 11, 2026$0.7745$0.7745$0.7305$0.74551.2M
Sep 10, 2026$0.7933$0.8274$0.76$0.7723.79M
Sep 9, 2026$0.8038$0.8264$0.7922$0.795742.16K
Sep 8, 2026$0.83$0.8435$0.7921$0.8051.15M

Latest ONCY news

The latest Smart Investors Daily articles mentioning ONCY.

Stock researchCompany · Overview

ONCY research

Overview

Company profile and research snapshot.

Company profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ONCY recent ratings
DateFirmRatingTarget
Aug 12, 2025H.C. WAINWRIGHT & CO., LLCBuy—
Aug 11, 2025H.C. WAINWRIGHT & CO., LLCBuy—
Aug 8, 2025JONES TRADINGHold—
Aug 7, 2025JONES TRADINGHold—
Jul 9, 2025LEEDE JONES GABLEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based interventionSAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an immunologically inacti

Yahoo · Sep 28, 2026

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026 FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immu

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By